3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
6
Breast
5
Thoracic
4
Lymphoid
3
Genitourinary
3
Gastrointestinal
3
CNS
3
Other hematologic neoplasm
2
Head & Neck
2
Sarcoma
1
Gynecologic
1
Endocrine
1
Classical hematology
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Febrile Neutropenia
1
Disease
1
Interventions
fludarabine phosphate
9
Cyclophosphamide
8
Cyclosporine
7
Busulfan
6
Antilymphocyte Serum
6
fludarabine
5
Melphalan
5
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Rivaroxaban
3
Radiotherapy
3
Methylprednisolone
3
Filgrastim
3
Cord Blood Stem Cell Transplantation
3
thymoglobulin
2
ferric carboxymaltose
2
apixaban
2
Whole-Body Irradiation
2
Therapeutics
2
Methotrexate
2
Heparin, Low-Molecular-Weight
2
Hematologic Tests
2
Genetic Counseling
2
Fondaparinux
2
Enoxaparin
2
Educational Status
2
Drug Therapy
2
Dalteparin
2
Cytarabine
2
sulforaphane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Positron Emission Tomography Computed Tomography
×
Classical hematology
×
Clear all
NCT03429387
2022-05-17
PIPPIN
Peter MacCallum Cancer Centre, Australia
Phase NA
Completed
147 enrolled